Literature DB >> 15591787

Abi enhances Abl-mediated CDC2 phosphorylation and inactivation.

Tzu-Yang Lin1, Chiu-Hui Huang, Wen-Gang Chou, Jyh-Lyh Juang.   

Abstract

Abelson tyrosine kinase (Abl) is a non-receptor tyrosine kinase which is frequently coupled with adaptor proteins to interact with its substrates for the regulation of cytoskeleton rearrangement, cell growth and apoptosis in response to a variety of biological stimuli. The Abl interactor (Abi) family members were first identified as adaptor proteins of Abl for regulating Abl transforming and kinase activity. In the present study, we used a yeast two-hybrid screen to identify Cdc2 as a novel Abi-binding protein. This finding led us to investigate the role of Abi in linking Abl and Cdc2. These three proteins formed a trimeric complex in Drosophila and mammalian cells. The expression of Abi in cells greatly enhanced the formation of the Abl-Cdc2 complex, suggesting that Abi functions as an adaptor protein facilitating the binding between Abl and Cdc2. We show that Abi promotes Abl-mediated phosphorylation of Cdc2 at tyrosine 15 and inactivation of Cdc2 kinase activity. Furthermore, coexpression of Abl and Abi in Drosophila S2 cells led to suppression of cell growth. These data suggest that Abl signaling may be involved in the downregulation of Cdc2 kinase in cell cycle control. 2004 National Science Council, ROC and S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15591787     DOI: 10.1007/bf02254375

Source DB:  PubMed          Journal:  J Biomed Sci        ISSN: 1021-7770            Impact factor:   8.410


  13 in total

1.  CDK1-mediated phosphorylation of Abi1 attenuates Bcr-Abl-induced F-actin assembly and tyrosine phosphorylation of WAVE complex during mitosis.

Authors:  Chunmei Zhuang; Hongxing Tang; Sharmila Dissanaike; Everardo Cobos; Yunxia Tao; Zonghan Dai
Journal:  J Biol Chem       Date:  2011-09-07       Impact factor: 5.157

2.  Tracking of specific integrant clones in dogs treated with foamy virus vectors.

Authors:  Ken Ohmine; Yi Li; Thomas R Bauer; Dennis D Hickstein; David W Russell
Journal:  Hum Gene Ther       Date:  2010-12-19       Impact factor: 5.695

Review 3.  ABL tyrosine kinases: evolution of function, regulation, and specificity.

Authors:  John Colicelli
Journal:  Sci Signal       Date:  2010-09-14       Impact factor: 8.192

4.  The actin-cytoskeleton pathway and its potential role in inflammatory bowel disease-associated human colorectal cancer.

Authors:  Ziad Kanaan; Motaz Qadan; Maurice Robert Eichenberger; Susan Galandiuk
Journal:  Genet Test Mol Biomarkers       Date:  2010-06

5.  Partner proteins that interact with Clonorchis sinensis WD40-repeat protein.

Authors:  Tae Im Kim; Pyo Yun Cho; Shunyu Li; Sung-Tae Hong; Min-Ho Choi; Sung-Jong Hong
Journal:  Parasitol Res       Date:  2007-07-06       Impact factor: 2.289

6.  Functional mechanisms and roles of adaptor proteins in abl-regulated cytoskeletal actin dynamics.

Authors:  Mizuho Sato; Masahiro Maruoka; Tatsuo Takeya
Journal:  J Signal Transduct       Date:  2012-05-17

7.  The NESH/Abi-3-based WAVE2 complex is functionally distinct from the Abi-1-based WAVE2 complex.

Authors:  Saki Sekino; Yuriko Kashiwagi; Hitoshi Kanazawa; Kazuki Takada; Takashi Baba; Seiichi Sato; Hiroki Inoue; Masaki Kojima; Katsuko Tani
Journal:  Cell Commun Signal       Date:  2015-10-01       Impact factor: 5.712

8.  Cell cycle genes and ovarian cancer susceptibility: a tagSNP analysis.

Authors:  J M Cunningham; R A Vierkant; T A Sellers; C Phelan; D N Rider; M Liebow; J Schildkraut; A Berchuck; F J Couch; X Wang; B L Fridley; A Gentry-Maharaj; U Menon; E Hogdall; S Kjaer; A Whittemore; R DiCioccio; H Song; S A Gayther; S J Ramus; P D P Pharaoh; E L Goode
Journal:  Br J Cancer       Date:  2009-09-08       Impact factor: 7.640

9.  Abi1 gene silencing by short hairpin RNA impairs Bcr-Abl-induced cell adhesion and migration in vitro and leukemogenesis in vivo.

Authors:  Weidong Yu; Xiaolin Sun; Nancy Clough; Everardo Cobos; Yunxia Tao; Zonghan Dai
Journal:  Carcinogenesis       Date:  2008-05-02       Impact factor: 4.944

10.  Synergistic effects of proteasome inhibitor carfilzomib in combination with tyrosine kinase inhibitors in imatinib-sensitive and -resistant chronic myeloid leukemia models.

Authors:  L J Crawford; E T Chan; M Aujay; T L Holyoake; J V Melo; H G Jorgensen; S Suresh; B Walker; A E Irvine
Journal:  Oncogenesis       Date:  2014-03-03       Impact factor: 7.485

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.